| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
101,000,000 |
| Market
Cap: |
793.86(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7528 - $16.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 9.5 |
| Insider 3/6 Months : 10.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
230,000 |
330,000 |
350,000 |
| Total Buy Value |
$0 |
$310,500 |
$455,990 |
$472,790 |
| Total People Bought |
0 |
2 |
3 |
4 |
| Total Buy Transactions |
0 |
2 |
3 |
4 |
| Total Shares Sold |
0 |
0 |
6,201 |
140,082 |
| Total Sell Value |
$0 |
$0 |
$9,429 |
$134,803 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
1 |
9 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gasmi Mehdi |
Director |
– • – |
2018-02-12 |
4 |
D |
$6.85 |
$74,021 |
D/D |
(10,806) |
248,367 |
|
- |
|
| Gasmi Mehdi |
Director |
– • – |
2018-02-09 |
4 |
D |
$7.05 |
$80,603 |
D/D |
(11,433) |
259,173 |
|
- |
|
| Patterson Leone D |
CEO, President and Director |
• • – |
2018-02-09 |
4 |
D |
$7.05 |
$57,866 |
D/D |
(8,208) |
162,397 |
|
- |
|
| Carter Eric G |
Director |
– • – |
2017-09-07 |
4 |
A |
$0.00 |
$0 |
D/D |
48,000 |
48,000 |
|
- |
|
| Gasmi Mehdi |
Director |
– • – |
2017-08-21 |
4 |
D |
$2.50 |
$13,698 |
D/D |
(5,479) |
270,606 |
|
- |
|
| Countouriotis Athena |
SVP, Chief Medical Officer |
• – – |
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
| Patterson Leone D |
CEO, President and Director |
• • – |
2017-06-15 |
4 |
D |
$2.70 |
$25,367 |
D/D |
(9,395) |
170,605 |
|
- |
|
| Spivey Richard N. |
Director |
– • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
70,804 |
|
- |
|
| Finer Mitchell H. |
Director |
– • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
603,069 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
70,380 |
|
- |
|
| Cleveland Paul B |
Chief Executive Officer |
• • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
22,727 |
|
- |
|
| Schwartz Steven Daniel |
Director |
– • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
398,991 |
|
- |
|
| Machado Clarence Patrick |
Director |
– • – |
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
68,182 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2017-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,223 |
47,653 |
|
- |
|
| Gasmi Mehdi |
Director |
– • – |
2017-04-21 |
4 |
D |
$2.70 |
$1,774 |
D/D |
(657) |
276,085 |
|
- |
|
| Spivey Richard N. |
Director |
– • – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
48,077 |
48,077 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2017-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,704 |
45,430 |
|
- |
|
| Machado Clarence Patrick |
Director |
– • – |
2017-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
45,455 |
45,455 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2017-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,774 |
41,726 |
|
- |
|
| Gasmi Mehdi |
Director |
– • – |
2017-02-12 |
4 |
D |
$3.00 |
$38,379 |
D/D |
(12,793) |
276,742 |
|
- |
|
| Salzman Amber |
President and CEO |
• • – |
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
262,000 |
891,766 |
|
- |
|
| Patterson Leone D |
CFO |
• – – |
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
180,000 |
|
- |
|
| Gasmi Mehdi |
Chief Science & Tech Officer |
• – – |
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
289,535 |
|
- |
|
| Barone Samuel B. |
SVP, Clinical Development |
• – – |
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
58,000 |
172,335 |
|
- |
|
| Woiwode Thomas |
Director |
– • – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,449 |
34,503 |
|
- |
|
266 Records found
|
|
Page 5 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.39 (4.73%) 
